$ABEO

Alland Leila sold $65K of ABEO

Alland Leila sold 11,000 shares of ABEONA THERAPEUTICS INC. (ABEO) at $5.92 on 2026-06-30.

Original reporting
SEC EDGAR · Alland Leila
Published Jul 2, 2026, 4:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 7:33 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$ABEO
Neutral
medium confidence
Mentioned
$ABEO
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ABEONeutralLow
01

Why it matters

The newest disclosed fact is the director’s open-market sale of 11,000 shares at $5.9170 on June 30, with post-sale holdings of 162,614 shares and no stated pre-arranged 10b5-1 plan.

02

Market read

Traders may briefly monitor insider-selling signals, but the disclosure lacks any accompanying fundamental or regulatory catalyst.

03

What to watch

The article does not state whether other insiders sold, whether there were concurrent option exercises, or whether the company has upcoming catalysts that would contextualize the sale.

Relevance 3/10Novelty 3/10Timing: filed July 2, after-hours/next-session read-through for insider-selling sentiment

Background

The article is a primary-source SEC Form 4 insider transaction for Abeona Therapeutics (ABEO).

Company-level read

Ticker impact

$ABEONeutralMedium confidence
Context

Abeona Therapeutics director Alland Leila sold 11,000 shares in an open-market transaction on June 30 for about $65.1K.

Expected impact

Likely minimal near-term impact; any effect would be sentiment-driven and typically fades unless paired with other disclosures.

Evidence & confidence

The filing discloses a completed sale size and price, but provides no accompanying company news, guidance change, or enforcement/regulatory action.

Market effects

No clear sector read-through from a single small insider sale without additional company or clinical/regulatory updates.

None.

None.

Counterpoint

Insider sales can be driven by diversification, taxes, or pre-planned liquidity needs; the absence of a 10b5-1 plan does not automatically imply negative information.

Key entities

  • ABEO

    Abeona Therapeutics Inc., the company whose director transaction is disclosed.

  • Alland Leila

    Director of ABEO who sold shares via an open-market sale.

Related articles

$ABEOMedAI 8/10

A new CMS payment could help Medicare patients access ZEVASKYN

Abeona Therapeutics (Nasdaq: ABEO) said CMS granted ZEVASKYN (prademagene zamikeracel) NTAP status under the FY2027 Hospital Inpatient Prospective Payment System rule. Abeona said NTAP adds supplemental Medicare reimbursement for technologies showing substantial clinical improvement. The company also reiterated ZEVASKYN’s safety risks, including potential cancer risk and serious allergic reactions.